LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Angelini Ventures has already invested €125 million in 22 startups
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
The fresh capital will propel Cordance into its first-in-human clinical trial
Subscribe To Our Newsletter & Stay Updated
